ImmunityBio (IBRX) Competitors $2.58 -0.01 (-0.19%) As of 11:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IBRX vs. ELAN, ROIV, RVMD, RYTM, GRFS, LEGN, ABVX, AXSM, RNA, and CYTKShould you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Grifols (GRFS), Legend Biotech (LEGN), Abivax (ABVX), Axsome Therapeutics (AXSM), Avidity Biosciences (RNA), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. ImmunityBio vs. Its Competitors Elanco Animal Health Roivant Sciences Revolution Medicines Rhythm Pharmaceuticals Grifols Legend Biotech Abivax Axsome Therapeutics Avidity Biosciences Cytokinetics ImmunityBio (NASDAQ:IBRX) and Elanco Animal Health (NYSE:ELAN) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Does the media favor IBRX or ELAN? In the previous week, ImmunityBio and ImmunityBio both had 9 articles in the media. Elanco Animal Health's average media sentiment score of 0.85 beat ImmunityBio's score of 0.54 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 0 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, IBRX or ELAN? ImmunityBio has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Is IBRX or ELAN more profitable? Elanco Animal Health has a net margin of 9.68% compared to ImmunityBio's net margin of -648.57%. Elanco Animal Health's return on equity of 7.04% beat ImmunityBio's return on equity.Company Net Margins Return on Equity Return on Assets ImmunityBio-648.57% N/A -113.86% Elanco Animal Health 9.68%7.04%3.45% Do analysts recommend IBRX or ELAN? ImmunityBio currently has a consensus price target of $10.75, indicating a potential upside of 315.86%. Elanco Animal Health has a consensus price target of $17.33, indicating a potential downside of 5.77%. Given ImmunityBio's stronger consensus rating and higher probable upside, equities analysts plainly believe ImmunityBio is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Elanco Animal Health 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78 Which has higher valuation & earnings, IBRX or ELAN? Elanco Animal Health has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$14.74M165.77-$413.56M-$0.48-5.39Elanco Animal Health$4.44B2.06$338M$0.8621.39 Do institutionals and insiders hold more shares of IBRX or ELAN? 8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 76.8% of ImmunityBio shares are held by insiders. Comparatively, 0.9% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryElanco Animal Health beats ImmunityBio on 11 of the 15 factors compared between the two stocks. Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBRX vs. The Competition Export to ExcelMetricImmunityBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.44B$3.18B$5.80B$10.16BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-5.3921.4874.7325.99Price / Sales165.77301.34470.3491.76Price / CashN/A45.3337.0859.91Price / Book-4.549.6312.256.31Net Income-$413.56M-$53.32M$3.28B$270.66M7 Day Performance7.71%0.95%1.39%3.52%1 Month Performance4.66%9.68%7.70%6.79%1 Year Performance-25.93%13.38%64.01%28.29% ImmunityBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBRXImmunityBio2.3785 of 5 stars$2.59-0.2%$10.75+315.9%-28.5%$2.44B$14.74M-5.39590Analyst ForecastELANElanco Animal Health2.6536 of 5 stars$17.31-3.0%$17.33+0.1%+29.8%$8.61B$4.44B20.149,000ROIVRoivant Sciences2.8286 of 5 stars$12.52+1.0%$16.38+30.8%+16.4%$8.57B$29.05M-17.94860News CoverageOptions VolumeRVMDRevolution Medicines4.2667 of 5 stars$40.13+1.5%$69.92+74.2%+11.0%$7.50B$11.58M-8.92250Trending NewsAnalyst ForecastAnalyst RevisionRYTMRhythm Pharmaceuticals3.1774 of 5 stars$104.83+0.6%$101.57-3.1%+98.6%$6.99B$130.13M-34.95140Positive NewsGRFSGrifols3.9747 of 5 stars$9.74+0.6%$10.30+5.8%+9.0%$6.69B$7.45B8.3223,822News CoveragePositive NewsLEGNLegend Biotech3.2956 of 5 stars$35.98+5.1%$74.22+106.3%-32.0%$6.65B$627.24M-40.942,609Positive NewsABVXAbivax2.3345 of 5 stars$83.52+1.9%$92.33+10.5%+631.6%$6.29BN/A0.0061News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap DownAXSMAxsome Therapeutics4.9162 of 5 stars$122.70-0.6%$177.86+45.0%+35.1%$6.13B$385.69M-24.23380Positive NewsInsider TradeRNAAvidity Biosciences2.127 of 5 stars$46.75-1.0%$67.00+43.3%+1.2%$6.04B$10.90M-13.19190News CoverageAnalyst ForecastInsider TradeGap UpCYTKCytokinetics4.3293 of 5 stars$48.66-1.9%$75.38+54.9%-0.8%$5.79B$18.47M-9.48250Insider Trade Related Companies and Tools Related Companies ELAN Alternatives ROIV Alternatives RVMD Alternatives RYTM Alternatives GRFS Alternatives LEGN Alternatives ABVX Alternatives AXSM Alternatives RNA Alternatives CYTK Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IBRX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
